Harmonizing the interpretation of ‘efficacy’ in Section 3(d) with Article 27 of TRIPs
As most of our readers may know Novartis has filed an appeal against the decision of the IPAB in the Glivec case. The decision of the IPAB is troublesome for several reasons which have already been listed out by Shamnad in one of his previous posts. One of the principle questions of law before the SC in this appeal is going to be the interpretation of the term ‘Efficacy’ in Section 3(d). The addition of this term in Section 3(d) […]
Harmonizing the interpretation of ‘efficacy’ in Section 3(d) with Article 27 of TRIPs Read More »